1 (Bloomberg) -- Cephalon Inc. agreed to buy Mepha Gruppe, one of two drugmakers being sold by Germany's Merckle family, to gain generic drugs and double ...
Seroquel, which generated sales of $4.9 billion last year, is AstraZeneca's second-biggest seller after the ulcer treatment Nexium. “The evidence, looked at ...
The real panic will come as top sellers such as the heartburn pill Nexium and cholesterol buster Crestor lose their patents. 'The next five years will be ...
Patents for Nexium, an acid-reflux drug, expire between 2014 and 2019, and the core US patent for Seroquel, its drug for schizophrenia and bipolar disorder, ...
Its primary products include Arimidex for hormonal breast cancer; Crestor that provides treatment for managing cholesterol levels; Nexium for acid-related ...
Novartis has announced that it intends to exercise its option to purchase Nestlé's remaining 52% stake in eye-care group Alcon for $28.1 billion and ...
... world's biggest generic drugmaker to delay for three years generic competition to its top-selling drug, the extended-release heartburn treatment Nexium. ...
